Filing Details
- Accession Number:
- 0001209191-16-135721
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2016-08-05 16:57:12
- Reporting Period:
- 2016-03-02
- Filing Date:
- 2016-08-05
- Accepted Time:
- 2016-08-05 16:57:12
- Original Submission Date:
- 2016-03-03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1326732 | Xencor Inc | XNCR | Pharmaceutical Preparations (2834) | 201622502 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1591313 | R John Desjarlais | C/O Xencor, Inc. 111 West Lemon Avenue Monrovia CA 91016 | Sr. V.p., Research & Cso | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2016-03-02 | 11,265 | $12.01 | 46,444 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2016-03-03 | 6,888 | $0.59 | 53,332 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-03-03 | 2,635 | $12.00 | 50,697 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Footnotes
- Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted December 14, 2015.
- This Form 4 is being amended to correct the number of shares sold on 3/2/2016 from 11,625 shares to 11,265 shares and to correct the amount of securities beneficially owned following the reported transaction.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Billionaire Hedge Funds
